← back to search

Markus Graefen

Eppendorf (Germany) · DE
Area of research
Pulmonary and Respiratory Medicine · Surgery
Research interest
Research interests include Prostate Cancer Diagnosis and Treatment, Prostate Cancer Treatment and Research, Bladder and Urothelial Cancer Treatments, and Advanced Radiotherapy Techniques.
h-index
119
citations
81,972
works
1,766
NIH funding
primary concept
email

Recent publications

Survival Outcomes and Temporal Trends of Non-Surgical Management Vs Radical Cystectomy in Non-Organ-Confined Urothelial Bladder Cancer
Urology 2025cited by 21position: middledoi
Current Standards for Training in Robot-assisted Surgery and Endourology: A Systematic Review
European Urology 2024cited by 29position: middledoi
Adverse In-Hospital Outcomes after Radical Prostatectomy in Leukemia History Patients
Cancers 2024cited by 17position: middledoi
Survival after trimodal therapy in octogenarians with organ‐confined urothelial bladder cancer
British Journal of Urology 2024cited by 16position: middledoi
Prostate-Specific Antigen Level at the Time of Salvage Therapy After Radical Prostatectomy for Prostate Cancer and the Risk of Death
Journal of Clinical Oncology 2023cited by 63position: middledoi
Assessing the Impact of Positive Surgical Margins on Mortality in Patients Who Underwent Robotic Radical Prostatectomy: 20 Years’ Report from the EAU Robotic Urology Section Scientific Working Group
European Urology Oncology 2023cited by 48position: middledoi
Automated <scp>Ki</scp>‐67 labeling index assessment in prostate cancer using artificial intelligence and multiplex fluorescence immunohistochemistry
The Journal of Pathology 2023cited by 32position: middledoi
Development and External Validation of a Machine Learning Model for Prediction of Lymph Node Metastasis in Patients with Prostate Cancer
European Urology Oncology 2023cited by 19position: middledoi
Prostate Cancer–specific and All-cause Mortality After Robot-assisted Radical Prostatectomy: 20 Years’ Report from the European Association of Urology Robotic Urology Section Scientific Working Group
European Urology Oncology 2023cited by 18position: middledoi
PITX1 Is a Regulator of TERT Expression in Prostate Cancer with Prognostic Power
Cancers 2022cited by 16position: middledoi
Postoperative Radiotherapy of Prostate Cancer: Adjuvant versus Early Salvage
Biomedicines 2022cited by 1position: middledoi
Overall Survival After Systemic Treatment in High-volume Versus Low-volume Metastatic Hormone-sensitive Prostate Cancer: Systematic Review and Network Meta-analysis
European Urology Focus 2021cited by 62position: middledoi
Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis
Prostate Cancer and Prostatic Diseases 2021cited by 57position: middledoi
Options for Curative Treatment of Localized Prostate Cancer
Deutsches Ärzteblatt international 2021cited by 22position: middledoi
Kann die Progression eines Prostatakarzinoms während Active Surveillance durch serielle Magnetresonanztomographie verlässlich diagnostiziert werden?
Der Urologe 2021cited by 0position: middledoi
Long-term Outcomes of Salvage Lymph Node Dissection for Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: Not as Good as Previously Thought
European Urology 2020cited by 111position: middledoi
Intermediate-risk Prostate Cancer: Stratification and Management
European Urology Oncology 2020cited by 96position: middledoi
Objective assessment of intraoperative skills for robot‐assisted radical prostatectomy (RARP): results from the ERUS Scientific and Educational Working Groups Metrics Initiative
British Journal of Urology 2020cited by 70position: middledoi
Underestimation of Positron Emission Tomography/Computerized Tomography in Assessing Tumor Burden in Prostate Cancer Nodal Recurrence: Head-to-Head Comparison of <sup>68</sup> Ga-PSMA and <sup>11</sup> C-Choline in a Large, Multi-Institutional Series of Extended Salvage Lymph Node Dissections
The Journal of Urology 2020cited by 38position: middledoi
Correction to: The natural course of pT2 prostate cancer with positive surgical margin: predicting biochemical recurrence
World Journal of Urology 2020cited by 0position: middledoi
Persistent Prostate-Specific Antigen After Radical Prostatectomy and Its Impact on Oncologic Outcomes
European Urology 2019cited by 119position: middledoi
Effect of Extended Pelvic Lymph Node Dissection on Oncologic Outcomes in Patients with D'Amico Intermediate and High Risk Prostate Cancer Treated with Radical Prostatectomy: A Multi-Institutional Study
The Journal of Urology 2019cited by 98position: middledoi
Expression of CCCTC‐binding factor (CTCF) is linked to poor prognosis in prostate cancer
Molecular Oncology 2019cited by 22position: middledoi
Impact of Adherence to Multidisciplinary Recommendations for Adjuvant Treatment in Radical Prostatectomy Patients With High Risk of Recurrence
Clinical Genitourinary Cancer 2019cited by 16position: lastdoi
Molecular Evolution of Early-Onset Prostate Cancer Identifies Molecular Risk Markers and Clinical Trajectories
Cancer Cell 2018cited by 321position: middledoi
How can we expand active surveillance criteria in patients with low‐ and intermediate‐risk prostate cancer without increasing the risk of misclassification? Development of a novel risk calculator
British Journal of Urology 2018cited by 35position: middledoi
Loss of CCAAT‐enhancer‐binding protein alpha (CEBPA) is linked to poor prognosis in <i>PTEN</i> deleted and <i>TMPRSS2:ERG</i> fusion type prostate cancers
The Prostate 2018cited by 5position: middledoi
Adjuvant and Salvage Radiotherapy after Radical Prostatectomy in Prostate Cancer Patients
European Urology 2017cited by 95position: middledoi
Low-risk Prostate Cancer: Identification, Management, and Outcomes
European Urology 2017cited by 81position: middledoi
Trends in Radical Prostatectomy Risk Group Distribution in a European Multicenter Analysis of 28 572 Patients: Towards Tailored Treatment
European Urology Focus 2017cited by 58position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Francesco Montorsi · Atlanta VA Medical Center20 papers (2012–2024)Alberto Briganti · Collaborative Group (United States)14 papers (2012–2024)Derya Tilki · Koç University11 papers (2016–2024)Giorgio Gandaglia · Vita-Salute San Raffaele University10 papers (2014–2025)Felix K.‐H. Chun · Goethe University Frankfurt10 papers (2012–2025)Guido Sauter · Collaborative Group (United States)9 papers (2012–2023)Pierre I. Karakiewicz · Université de Montréal9 papers (2012–2025)Alexandre Mottrie · University of Florence9 papers (2012–2024)Hartwig Huland · Charité - Universitätsmedizin Berlin8 papers (2012–2023)Ronald Simon · Universität Hamburg7 papers (2012–2023)Zhe Tian · Hainan Normal University7 papers (2012–2025)Peter Wiklund · Mount Sinai Hospital7 papers (2012–2024)Fred Saad · Cytodiagnostics (Canada)6 papers (2012–2024)R. Jeffrey Karnes · Mayo Clinic6 papers (2012–2017)Shahrokh F. Shariat · University Hospital in Motol6 papers (2012–2024)Vipul Patel · Virginia Commonwealth University6 papers (2012–2023)Thorsten Schlomm · Universität Hamburg6 papers (2012–2023)Prasanna Sooriakumaran · University College London Hospitals NHS Foundation Trust5 papers (2015–2019)Giacomo Novara · University of Padua5 papers (2012–2015)Sarah Minner · Universität Hamburg5 papers (2012–2023)